Ocular Therapeutix (OCUL) director granted RSUs and 44,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Ocular Therapeutix director Merilee Raines received new equity awards. On June 10, 2026, she was granted 14,000 restricted stock units, each representing one share of common stock, under the company’s 2021 Stock Incentive Plan.
Subject to her continued board service, these RSUs vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, whichever comes first. She also received stock options for 44,000 shares at an exercise price of $8.74 per share, expiring on June 9, 2036, with similar vesting conditions. Following the grant, she directly holds 60,933 shares of common stock, in addition to the new option award.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
RAINES MERILEE
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 44,000 | $0.00 | -- |
| Grant/Award | Common Stock | 14,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 44,000 shares (Direct, null);
Common Stock — 60,933 shares (Direct, null)
Footnotes (1)
- On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
Key Figures
RSU grant: 14,000 RSUs
Shares held after grant: 60,933 shares
Stock options granted: 44,000 options
+2 more
5 metrics
RSU grant
14,000 RSUs
Granted June 10, 2026 under 2021 Stock Incentive Plan
Shares held after grant
60,933 shares
Common stock directly held following RSU grant
Stock options granted
44,000 options
Right to buy common stock granted June 10, 2026
Option exercise price
$8.74 per share
Conversion or exercise price for 44,000 options
Option expiration
June 9, 2036
Expiration date of stock options granted
Key Terms
restricted stock units ("RSUs"), 2021 Stock Incentive Plan, Stock Option (Right to Buy), vesting
4 terms
restricted stock units ("RSUs") financial
"the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2021 Stock Incentive Plan financial
"granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc."
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting financial
"the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What equity awards did Ocular Therapeutix (OCUL) director Merilee Raines receive?
Merilee Raines received 14,000 restricted stock units and stock options for 44,000 shares. The RSUs convert into common stock, and the options have a set exercise price, expanding her long-term equity-based compensation.
When do Merilee Raines’s new Ocular Therapeutix (OCUL) RSUs vest?
The 14,000 RSUs vest 100% on the first anniversary of the June 10, 2026 grant date. Alternatively, they vest earlier immediately before the next annual stockholder meeting, if that occurs sooner, assuming she continues serving on the board.
What are the key terms of Merilee Raines’s new stock options at Ocular Therapeutix (OCUL)?
Raines received options for 44,000 shares of common stock with an $8.74 exercise price. These options vest in full on the first anniversary of the grant date or earlier before the next annual stockholder meeting and expire on June 9, 2036.
Are Merilee Raines’s new equity awards at Ocular Therapeutix (OCUL) market purchases?
No. The filing shows these awards as grants under the 2021 Stock Incentive Plan, not open-market purchases. Both the RSUs and options were acquired at a reported price of $0.00 per share as part of her director compensation.